-
EP4077365
European procedure
- EP About this file
- EP Legal status
- EP Federated register
- EP Event history
- EP Citations
- EP Patent family
- EP All documents
Extract from the Register of European Patents
EP About this file: EP4077365
| EP4077365 - INCRETIN ANALOGS AND USES THEREOF [Right-click to bookmark this link] | Status | Request for examination was made Status updated on 23.09.2022 Database last updated on 24.08.2024 | |
| Former | The international publication has been made Status updated on 25.06.2021 | ||
| Former | unknown Status updated on 22.01.2021 | Most recent event Tooltip | 19.01.2024 | Change - representative | Applicant(s) | For all designated states ELI LILLY AND COMPANY Lilly Corporate Center Indianapolis, IN 46206-6288 / US | [2022/43] | Inventor(s) | 01 /
ABRAHAM, Milata Mary c/o Eli Lilly and Company P.O. Box 6288 Indianapolis, Indiana 46206-6288 / US | 02 /
ALSINA-FERNANDEZ, Jorge c/o Eli Lilly and Company P.O. Box 6288 Indianapolis, Indiana 46206-6288 / US | 03 /
COSKUN, Tamer c/o Eli Lilly and Company P.O. Box 6288 Indianapolis, Indiana 46206-6288 / US | 04 /
QU, Hongchang c/o Eli Lilly and Company P.O. Box 6288 Indianapolis, Indiana 46206-6288 / US | 05 /
WALLIS, James Lincoln c/o Eli Lilly and Company P.O. Box 6288 Indianapolis, Indiana 46206-6288 / US | [2022/43] | Representative(s) | Boanas-Evans, Duncan Richard Eli Lilly and Company Limited 8 Arlington Square West Downshire Way Bracknell, Berkshire RG12 1PU / GB | [N/P] |
| Former [2022/43] | Kent, Lindsey Ruth Eli Lilly and Company Limited 8 Arlington Square West Downshire Way Bracknell, Berkshire RG12 1PU / GB | Application number, filing date | 20839440.3 | 11.12.2020 | [2022/43] | WO2020US64512 | Priority number, date | US201962949661P | 18.12.2019 Original published format: US 201962949661 P | [2022/43] | Filing language | EN | Procedural language | EN | Publication | Type: | A1 Application with search report | No.: | WO2021126695 | Date: | 24.06.2021 | Language: | EN | [2021/25] | Type: | A1 Application with search report | No.: | EP4077365 | Date: | 26.10.2022 | Language: | EN | The application published by WIPO in one of the EPO official languages on 24.06.2021 takes the place of the publication of the European patent application. | [2022/43] | Search report(s) | International search report - published on: | EP | 24.06.2021 | Classification | IPC: | C07K14/605, A61K38/26 | [2022/43] | CPC: |
C07K14/605 (EP,IL,KR);
C07K14/575 (US);
A61K38/00 (EP,IL,US);
A61K38/26 (KR);
A61P3/04 (US);
A61P3/06 (US);
A61P3/10 (KR,US)
(-)
| Designated contracting states | AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR [2022/43] | Extension states | BA | 18.07.2022 | ME | 18.07.2022 | Validation states | MA | 18.07.2022 | MD | 18.07.2022 | TN | 18.07.2022 | Title | German: | INCRETIN-ANALOGA UND VERWENDUNGEN DAVON | [2022/43] | English: | INCRETIN ANALOGS AND USES THEREOF | [2022/43] | French: | ANALOGUES D'INCRÉTINE ET LEURS UTILISATIONS | [2022/43] | Entry into regional phase | 18.07.2022 | National basic fee paid | 18.07.2022 | Designation fee(s) paid | 18.07.2022 | Examination fee paid | Examination procedure | 30.06.2022 | Amendment by applicant (claims and/or description) | 18.07.2022 | Examination requested [2022/43] | 18.07.2022 | Date on which the examining division has become responsible | Fees paid | Renewal fee | 02.01.2023 | Renewal fee patent year 03 | 02.01.2024 | Renewal fee patent year 04 |
| Opt-out from the exclusive Tooltip competence of the Unified Patent Court | See the Register of the Unified Patent Court for opt-out data | ||
| Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court. | Cited in | International search | [Y]WO2016111971 (LILLY CO ELI [US]) [Y] 1-43 * see the whole document and in particular claim 1 *; | [Y]US2016310575 (BELLI SARA [CH], et al) [Y] 1-43 * see the whole document and in particular claim 11 *; | [Y]CA3084004 (LILLY CO ELI [US]) [Y] 1-43 * see the whole document and in particular claim 1 *; | [Y]CA3084005 (LILLY CO ELI [US]) [Y] 1-43 * see the whole document and in particular claim 1 *; | [Y] - BASTIN MARIE ET AL, "Dual GIP-GLP1-Receptor Agonists In The Treatment Of Type 2 Diabetes: A Short Review On Emerging Data And Therapeutic Potential", DIABETES, METABOLIC SYNDROME AND OBESITY: TARGETS AND THERAPY, Volume 12, doi:10.2147/DMSO.S191438, (20190930), pages 1973 - 1985, URL: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6777434/pdf/dmso-12-1973.pdf, XP055797753 [Y] 1-43 * see the whole document and in particular Figure 2 * DOI: http://dx.doi.org/10.2147/DMSO.S191438 | [A] - PIOTR A. MROZ ET AL, "Optimized GIP analogs promote body weight lowering in mice through GIPR agonism not antagonism", MOLECULAR METABOLISM, (20181205), vol. 20, doi:10.1016/j.molmet.2018.12.001, ISSN 2212-8778, pages 51 - 62, XP055725248 [A] 1-43 * the whole document * DOI: http://dx.doi.org/10.1016/j.molmet.2018.12.001 | by applicant | WO2014049610 | WO2015067716 | WO2016198624 | WO2017116204 | WO2017153575 | - CASAGRANDE et al., Diabetes Care, (20130000), vol. 36, pages 2271 - 2279 | - JAIL et al., Mol. Metab., (20170000), vol. 6, pages 440 - 446 | - CARBONE et al., J. Gastroenterol. Hepatol., (20160000), vol. 31, pages 23 - 31 | - FINAN et al., Trends Mol. Med., (20160000), vol. 22, pages 359 - 376 | - CHOI et al., "Potent body weight loss and efficacy in a NASH animal model by a novel long-acting GLP-IlGlucagonIGIP triple-agonist (HM15211)", ADA Poster, (20170000), page 1139 | - DING, J. Bone Miner. Res., (20080000), vol. 23, pages 536 - 543 | - TAI et al., Brain Res, (20180000), vol. 1678, pages 64 - 74 | - MIILLER et al., Physiol. Rev., (20170000), vol. 97, pages 721 - 766 | - FINAN et al., Sci. Transl. Med., (20130000), vol. 5, page 209 | - HOLSCHER, Biochem. Soc. Trans., (20140000), vol. 42, pages 593 - 600 |